Free Trial

Pliant Therapeutics (PLRX) Competitors

Pliant Therapeutics logo
$1.20 +0.03 (+2.56%)
Closing price 04:00 PM Eastern
Extended Trading
$1.21 +0.01 (+0.83%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLRX vs. AARD, OLMA, AVTE, OCGN, GLUE, AVIR, PRME, TKNO, RCKT, and LFCR

Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Aardvark Therapeutics (AARD), Olema Pharmaceuticals (OLMA), Aerovate Therapeutics (AVTE), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), Atea Pharmaceuticals (AVIR), Prime Medicine (PRME), Alpha Teknova (TKNO), Rocket Pharmaceuticals (RCKT), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry.

Pliant Therapeutics vs. Its Competitors

Pliant Therapeutics (NASDAQ:PLRX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

97.3% of Pliant Therapeutics shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Pliant Therapeutics presently has a consensus price target of $13.31, indicating a potential upside of 1,009.38%. Aardvark Therapeutics has a consensus price target of $33.00, indicating a potential upside of 144.08%. Given Pliant Therapeutics' higher possible upside, equities analysts plainly believe Pliant Therapeutics is more favorable than Aardvark Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pliant Therapeutics
0 Sell rating(s)
12 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Aardvark Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Aardvark Therapeutics had 7 more articles in the media than Pliant Therapeutics. MarketBeat recorded 8 mentions for Aardvark Therapeutics and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Aardvark Therapeutics' score of 0.79 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pliant Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aardvark Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Aardvark Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$1.58M46.63-$210.30M-$3.61-0.33
Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A

Aardvark Therapeutics' return on equity of 0.00% beat Pliant Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pliant TherapeuticsN/A -67.56% -52.54%
Aardvark Therapeutics N/A N/A N/A

Summary

Aardvark Therapeutics beats Pliant Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Pliant Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLRX vs. The Competition

MetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$71.82M$2.90B$5.49B$8.93B
Dividend YieldN/A2.69%5.38%4.13%
P/E RatioN/A21.3126.2119.90
Price / Sales46.63241.40405.84161.31
Price / CashN/A41.8936.4957.06
Price / Book0.247.518.055.38
Net Income-$210.30M-$55.05M$3.15B$248.50M
7 Day Performance-13.04%2.45%1.85%2.97%
1 Month Performance-16.67%7.33%4.81%6.02%
1 Year Performance-88.68%5.38%34.86%20.39%

Pliant Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLRX
Pliant Therapeutics
4.244 of 5 stars
$1.20
+2.6%
$13.31
+1,009.4%
-89.2%$71.82M$1.58M0.0090Gap Up
AARD
Aardvark Therapeutics
N/A$13.33
+19.8%
$31.25
+134.4%
N/A$289.26MN/A0.0018News Coverage
Analyst Forecast
Analyst Revision
Gap Down
OLMA
Olema Pharmaceuticals
2.6734 of 5 stars
$4.19
+1.5%
$24.50
+484.7%
-60.8%$286.68MN/A-2.0870News Coverage
Positive News
AVTE
Aerovate Therapeutics
N/A$9.89
+5.1%
N/A-83.2%$286.66MN/A-3.3120Gap Down
High Trading Volume
OCGN
Ocugen
1.3297 of 5 stars
$0.98
-7.4%
$6.00
+511.6%
-43.1%$286.51M$4.52M-5.1680High Trading Volume
GLUE
Monte Rosa Therapeutics
1.8015 of 5 stars
$4.64
+0.2%
$15.50
+234.1%
+17.0%$285.41M$75.62M58.0190Positive News
AVIR
Atea Pharmaceuticals
3.1131 of 5 stars
$3.32
+2.2%
$6.00
+80.7%
+6.8%$284.13MN/A-2.0170News Coverage
PRME
Prime Medicine
3.6756 of 5 stars
$2.16
+4.3%
$10.08
+366.8%
-50.2%$283.60M$3.85M-1.05234High Trading Volume
TKNO
Alpha Teknova
3.0127 of 5 stars
$5.28
-5.0%
$8.50
+61.0%
+307.4%$282.16M$37.74M-11.00240News Coverage
RCKT
Rocket Pharmaceuticals
4.9145 of 5 stars
$2.63
-2.6%
$18.60
+607.2%
-87.5%$280.86MN/A-1.00240
LFCR
Lifecore Biomedical
1.5996 of 5 stars
$7.39
+6.5%
$8.00
+8.3%
+68.6%$273.65M$128.26M-5.10690Positive News

Related Companies and Tools


This page (NASDAQ:PLRX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners